ESSA Pharma Inc

NASDAQ EPIX

Data sourced from iex and EODHD
Download Data

ESSA Pharma Inc Exchange Rate Adjustment 2 year CAGR for the year ending September 19, 2024

ESSA Pharma Inc Exchange Rate Adjustment 2 year CAGR is NA for the year ending September 19, 2024. Exchange Rate Adjustment reflects the impact of changes in foreign exchange rates on a company's cash balance when converting from one currency to another. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: EPIX

ESSA Pharma Inc

CEO Dr. David Ross Parkinson M.D.
IPO Date July 9, 2015
Location Canada
Headquarters 999 West Broadway, Vancouver, BC, Canada, V5Z 1K5
Employees 50
Sector Healthcare
Industry Biotechnology
Description

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

StockViz Staff

September 19, 2024

Any question? Send us an email